Literature DB >> 29769384

Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources.

Rachel P Riechelmann1, Julien Péron2,3, Bostjan Seruga4, Everardo D Saad5,6.   

Abstract

"Meta-research" is a discipline that investigates research practices. Meta-research on clinical trials is an attempt to summarize descriptive and methodological features of published or ongoing clinical trials, including aspects of their implementation, design, analysis, reporting, and interpretation. In this type of investigation, the unit of analysis is a primary source of information about a clinical trial (e.g., published reports, study protocols, or abstracts), with meta-research being a second layer of information that summarizes what is known from various primary sources. After the formulation of the primary research question, the methodology of meta-research resembles that of other research projects, with predefined eligibility criteria, exposure variables, primary and secondary outcomes of interest, and an analysis plan. This type of study usually provides a high-level picture of the literature on a specific topic, always accompanied by a critical evaluation of the methodology and/or the quality of reporting of the studies included. Because relatively few resources are consumed to produce meta-research, these studies offer a great opportunity for clinical scientists working in settings with limited resources. In this article, we present the principles of designing and conducting meta-research and use our experience to suggest recommendations on how to perform and how to report this type of potentially very creative study. IMPLICATIONS FOR PRACTICE: The term meta-research pertains to a type of study in which the unit of analysis is, in most cases, the publication of a clinical trial. This type of study usually provides a high-level picture of the literature on a specific topic, always accompanied by a critical evaluation of the methodology, design, and/or the quality of reporting of the studies included. Because relatively few resources are consumed to produce meta-research, these studies offer a great opportunity for clinical scientists who work in low-income countries. This article presents the principles of designing and conducting meta-research and proposes practical recommendations on how to perform and report this type of potentially very creative study. © AlphaMed Press 2018.

Keywords:  Cancer; Clinical trials; Global oncology; Meta‐research; Methodology

Mesh:

Year:  2018        PMID: 29769384      PMCID: PMC6292557          DOI: 10.1634/theoncologist.2018-0043

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  29 in total

Review 1.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials.

Authors:  Tatiana Goberstein Lerner; Michele da Costa Miranda; Andrea Thaumaturgo Lera; Aline Ueda; Bruna Briones; Auro Del Giglio; Rachel Riechelmann
Journal:  Contemp Clin Trials       Date:  2012-06-01       Impact factor: 2.226

3.  Making PubMed searching simple: learning to retrieve medical literature through interactive problem solving.

Authors:  Beatriz Vincent; Maurice Vincent; Carlos Gil Ferreira
Journal:  Oncologist       Date:  2006-03

4.  Trial watch: phase II and phase III attrition rates 2011-2012.

Authors:  John Arrowsmith; Philip Miller
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

5.  Randomisation and baseline comparisons in clinical trials.

Authors:  D G Altman; C J Doré
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

6.  Subgroup analysis and other (mis)uses of baseline data in clinical trials.

Authors:  S F Assmann; S J Pocock; L E Enos; L E Kasten
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

7.  Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects.

Authors:  Everardo D Saad; Marc Buyse
Journal:  Acta Oncol       Date:  2012-09       Impact factor: 4.089

8.  Evolution of the randomized controlled trial in oncology over three decades.

Authors:  Christopher M Booth; David W Cescon; Lisa Wang; Ian F Tannock; Monika K Krzyzanowska
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

Review 9.  Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.

Authors:  A Srikanthan; F Vera-Badillo; J Ethier; R Goldstein; A J Templeton; A Ocana; B Seruga; E Amir
Journal:  Cancer Treat Rev       Date:  2015-12-31       Impact factor: 12.111

10.  Meta-research: Evaluation and Improvement of Research Methods and Practices.

Authors:  John P A Ioannidis; Daniele Fanelli; Debbie Drake Dunne; Steven N Goodman
Journal:  PLoS Biol       Date:  2015-10-02       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.